Literature DB >> 33466666

Might Fibroblasts from Patients with Alzheimer's Disease Reflect the Brain Pathology? A Focus on the Increased Phosphorylation of Amyloid Precursor Protein Tyr682 Residue.

Filomena Iannuzzi1, Vincenza Frisardi2, Lucio Annunziato3, Carmela Matrone4.   

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure and no effective diagnostic criteria. The greatest challenge in effectively treating AD is identifying biomarkers specific for each patient when neurodegenerative processes have not yet begun, an outcome that would allow the design of a personalised therapeutic approach for each patient and the monitoring of the therapeutic response during the treatment. We found that the excessive phosphorylation of the amyloid precursor protein (APP) Tyr682 residue on the APP 682YENPTY687 motif precedes amyloid β accumulation and leads to neuronal degeneration in AD neurons. We proved that Fyn tyrosine kinase elicits APP phosphorylation on Tyr682 residue, and we reported increased levels of APP Tyr682 and Fyn overactivation in AD neurons. Here, we want to contemplate the possibility of using fibroblasts as tools to assess APP Tyr682 phosphorylation in AD patients, thus making the changes in APP Tyr682 phosphorylation levels a potential diagnostic strategy to detect early pathological alterations present in the peripheral cells of AD patients' AD brains.

Entities:  

Keywords:  Alzheimer’s disease; Fyn tyrosine kinase; Tyr682 residue; YENPTY motif; amyloid beta; amyloid precursor protein

Year:  2021        PMID: 33466666      PMCID: PMC7828817          DOI: 10.3390/brainsci11010103

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  23 in total

1.  Tyr682 in the Aβ-precursor protein intracellular domain regulates synaptic connectivity, cholinergic function, and cognitive performance.

Authors:  Carmela Matrone; Siro Luvisetto; Luca R La Rosa; Robert Tamayev; Annabella Pignataro; Nadia Canu; Li Yang; Alessia P M Barbagallo; Fabrizio Biundo; Franco Lombino; Hui Zheng; Martine Ammassari-Teule; Luciano D'Adamio
Journal:  Aging Cell       Date:  2012-10-12       Impact factor: 9.304

Review 2.  The Y682ENPTY687 motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients.

Authors:  Carmela Matrone; Filomena Iannuzzi; Lucio Annunziato
Journal:  Ageing Res Rev       Date:  2019-04-27       Impact factor: 10.895

3.  Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Authors:  Jinho Kim; Daniel J Amante; Jennifer P Moody; Christina K Edgerly; Olivia L Bordiuk; Karen Smith; Samantha A Matson; Wayne R Matson; Clemens R Scherzer; H Diana Rosas; Steven M Hersch; Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2010-05-09

4.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21.

Authors:  P H St George-Hyslop; R E Tanzi; R J Polinsky; J L Haines; L Nee; P C Watkins; R H Myers; R G Feldman; D Pollen; D Drachman
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

5.  Expression of the Alzheimer's Disease Mutations AβPP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs.

Authors:  Jannik E Jakobsen; Marianne G Johansen; Mette Schmidt; Ying Liu; Rong Li; Henrik Callesen; Margarita Melnikova; Mette Habekost; Carmela Matrone; Yvonne Bouter; Thomas A Bayer; Anders Lade Nielsen; Monika Duthie; Paul E Fraser; Ida E Holm; Arne Lund Jørgensen
Journal:  J Alzheimers Dis       Date:  2016-07-14       Impact factor: 4.472

6.  Glycogen synthase kinase 3 β activity is essential for Polo-like kinase 2- and Leucine-rich repeat kinase 2-mediated regulation of α-synuclein.

Authors:  Rikke H Kofoed; Cristine Betzer; Nelson Ferreira; Poul Henning Jensen
Journal:  Neurobiol Dis       Date:  2019-12-24       Impact factor: 5.996

7.  New Insights to Clathrin and Adaptor Protein 2 for the Design and Development of Therapeutic Strategies.

Authors:  Ebbe Toftgaard Poulsen; Agnete Larsen; Alen Zollo; Arne L Jørgensen; Kristian W Sanggaard; Jan J Enghild; Carmela Matrone
Journal:  Int J Mol Sci       Date:  2015-12-10       Impact factor: 5.923

8.  Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.

Authors:  K Lakshmi Narayanan; Vanita Chopra; H Diana Rosas; Keith Malarick; Steven Hersch
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

Review 9.  Protein Kinases and Parkinson's Disease.

Authors:  Syed Jafar Mehdi; Hector Rosas-Hernandez; Elvis Cuevas; Susan M Lantz; Steven W Barger; Sumit Sarkar; Merle G Paule; Syed F Ali; Syed Z Imam
Journal:  Int J Mol Sci       Date:  2016-09-20       Impact factor: 5.923

10.  Tau interacts with src-family non-receptor tyrosine kinases.

Authors:  G Lee; S T Newman; D L Gard; H Band; G Panchamoorthy
Journal:  J Cell Sci       Date:  1998-11       Impact factor: 5.285

View more
  3 in total

Review 1.  The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.

Authors:  Margrethe A Olesen; Francisca Villavicencio-Tejo; Rodrigo A Quintanilla
Journal:  Transl Neurodegener       Date:  2022-07-04       Impact factor: 9.883

Review 2.  CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Neurotox Res       Date:  2022-08-31       Impact factor: 3.978

3.  Tandem Mass Spectrometry as Strategy for the Selective Identification and Quantification of the Amyloid Precursor Protein Tyr682 Residue Phosphorylation Status in Human Blood Mononuclear Cells.

Authors:  Pierluigi Reveglia; Rosarita Nasso; Antonella Angiolillo; Lucia Lecce; Carmela Paolillo; Samantha De Tullio; Monica Gelzo; Alfonso Di Costanzo; Carmela Matrone; Gaetano Corso
Journal:  Biomolecules       Date:  2021-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.